Evidence map›Paper›PMID 33658922›Full record

ArticleFrontiers in pharmacology2020

Monitoring Tacrolimus Trough Concentrations During the First Year After Kidney Transplantation: A National Retrospective Cohort Study.

Sarah S Alghanem, Moetaza M Soliman, Ali A Alibrahim, Osama Gheith, Ahmed S Kenawy, Abdelmoneim Awad

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Evaluation of efficacy and safety of generic tacrolimus (SuprotacEuropean journal of translational myology · 2025
    Article
  5. Review
  6. Analysis of risk factors and establishment of a risk prediction model for post-transplant diabetes mellitus after kidney transplantation.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Sarah S AlghanemDepartment of Pharmacy Practice, Kuwait University, Kuwait City, Kuwait.
Moetaza M SolimanDepartment of Pharmacy Practice, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Ali A AlibrahimPharmacy Department, Manahi Al-Osaimi Health Centre, Ministry of Health, Kuwait City, Kuwait.
Osama GheithNephrology Department, Hamed Al-Essa Organ Transplant Centre, Ministry of Health, Kuwait City, Kuwait.
Ahmed S KenawyPharmacy Department, Hamed Al-Essa Organ Transplant Centre, Ministry of Health, Kuwait city, Kuwait.
Abdelmoneim AwadDepartment of Pharmacy Practice, Kuwait University, Kuwait City, Kuwait.
Ministry of Health · KWKuwait University · KWMansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

calcinurin inhibitorskidney transplantationposttransplant diabetesposttransplant dyslipidemiaposttransplant hypertensiontacrolimus

Identifiers

PMID33658922
PMCPMC7919378
OpenAlexW3107480166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.